Abstract:Aims The differential diagnosis between ALK-negative anaplastic large cell lymphoma (ALK - ALCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) with high expression of CD30 (CD30 high ) are essential. However, no reliable biomarker is available in daily practice except CD30. STAT3 is characteristically activated in ALCL. We aimed to investigate whether the status of STAT3 phosphorylation could help the differential diagnosis. Methods The status of phosphorylation of STAT3 was examined using two antibodies against pSTAT3-Y705 and pSTAT3-S727 by immunohistochemistry in ALK + ALCL (n=33), ALK - ALCL (n=22) and PTCL, NOS (n=34). Ten PTCL, NOS with diffuse CD30 expression were defined as CD30 high PTCL, NOS. Flowcytometric analysis were performed to evaluate the expression of pSTAT3-Y705/S727 in PTCL, NOS (n=3). Results The median H-scores of pSTAT3-Y705 and S727 were 280 and 260 in ALK + ALCL, 250 and 240 in ALK - ALCL, and 45 and 75 in CD30 high subgroup, respectively. Using H score of 145 as the cutoff value, pSTAT3-S727 alone distinguished between ALK - ALCL and CD30 high PTCL, NOS with a sensitivity of 100% and specificity of 83%. Additionally, pSTAT3-S727, but not pSTAT3-Y705, was also expressed by background tumor-infiltrating lymphocytes (S727 TILs ) in PTCL, NOS. PTCL, NOS patients with high S727 TILs H score had a favorable prognosis than those with no TILs (3-year OS rate: 43% vs. 0, p =0.013) or low S727 TILs (3-year OS rate: 43% vs. 0, p =0.099). Flowcytometric analysis revealed that of the three patients investigated, two had enhanced pSTAT-S727 signals in neoplastic cell populations, and all three patients were negative for pSTAT3-Y705 expression in both tumor cells and background lymphocytes. Conclusions pSTAT3-Y705/S727 can be used to help distinguish ALK - ALCL from CD30 high PTCL, NOS and pSTAT3-S727 expression by TILs predicts the prognosis of a subset of PTCL, NOS.

STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target

Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion

Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

Data from Clinical Implications of Phosphorylated STAT3 Expression in <i>de Novo</i> Diffuse Large B-cell Lymphoma

STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma

Expression and Functions of the STAT3-SCLIP Pathway in Chronic Myeloid Leukemia Cells.

ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions

Clinical significance and prognostic value of STAT 3 expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases

Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma

Phosphoproteomic Analysis of Anaplastic Lymphoma Kinase (alk) Downstream Signaling Pathways Identifies Signal Transducer and Activator of Transcription 3 As A Functional Target of Activated Alk in Neuroblastoma Cells

Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway

Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK- ALCL vs. CD30high PTCL, NOS

ALK-positive large B-cell lymphoma (ALK + LBCL) with aberrant CD3 expression

Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma

ALK: a tyrosine kinase target for cancer therapy

STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK− ALCL

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma

TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature